Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting
EWING, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA).
Moderated Poster PresentationThe poster entitled “Comparison of Pharmacokinetic Profiles of Testosterone Therapy Products in Relation to Diurnal Variation of Serum Testosterone Levels” will be presented by Alexander Pastuszak, MD, PhD, University of Utah School of Medicine, Salt Lake City, Utah. The submission was among a select group of key abstracts awarded the distinction of a moderated poster presentation.The goal of the study was to review the pharmacokinetic (PK) profiles of serum testosterone in different exogenous testosterone formulations and compare these PK profiles with daily variations in endogenous serum testosterone levels. A review of daily testosterone variation studies in adult men was conducted followed by literature searches and product prescribing information review of a variety of testosterone therapies. Routes of administration considered were subcutaneous testosterone enanthate (XYOSTED®), intramuscular testosterone, topical testosterone gel, topical testosterone solution, subdermal pellets, nasal testosterone gel, oral testosterone and the testosterone buccal system.Date: Saturday, October 26, 2019 – 1:50 p.m.
Session: Moderated Poster Session: Androgens
Session Time: 1:30 p.m. – 3:00 p.m. Eastern Time
Location: OMNI Nashville Hotel, Nashville, Tennessee e-Poster PresentationThe poster entitled “Testosterone Patient Journey Analysis” will be presented by Irwin Goldstein, MD, San Diego Sexual Medicine, San Diego, California.Male hypogonadism is a clinical syndrome resultant of pathological failure within the hypothalamic-pituitary-testicular axis that normally produces physiological required concentrations of testosterone. Erectile dysfunction, fatigue/lethargy, depressive symptoms, and decreased energy and libido are common symptoms associated with decreased testosterone concentrations. Testosterone therapy is clinically recommended in men with hypogonadism. An analysis of the hypogonadal patient journey was conducted to explore the initial symptoms, impact of initial treatment, and patients’ concerns and current mindset about testosterone replacement therapy.Date: Saturday, October 26, 2019 – 10:11 a.m.
Session: Androgens – e-Poster session 10
Session Time: 10:05 a.m. – 10:30 a.m. Eastern Time
Location: OMNI Nashville Hotel, Nashville, Tennessee About SMSNA